These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 34019333

  • 1. Alectinib-responsive infantile anaplastic ganglioglioma with a novel VCL-ALK gene fusion.
    Yamamoto S, Koga Y, Ono H, Goto H, Hata N, Yamamoto H, Suzuki SO, Sakai Y, Iwaki T, Ohga S.
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29122. PubMed ID: 34019333
    [No Abstract] [Full Text] [Related]

  • 2. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM.
    Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
    [Abstract] [Full Text] [Related]

  • 3. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
    Hui B, Zhang J, Shi X, Xing F, Shao YW, Wang Y, Zhang X, Wang S.
    Jpn J Clin Oncol; 2020 Dec 16; 50(12):1470-1474. PubMed ID: 32845005
    [Abstract] [Full Text] [Related]

  • 4. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    Hu S, Li Q, Peng W, Feng C, Zhang S, Li C.
    J Thorac Oncol; 2018 May 16; 13(5):e72-e74. PubMed ID: 29703539
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
    Shiihara J, Ohyanagi F, Amari H, Toda M, Tahara H, Yuzawa M, Maeda Y, Nomura M, Mizushina Y, Nagai Y, Ohta H, Yamaguchi Y.
    Thorac Cancer; 2021 Sep 16; 12(17):2420-2423. PubMed ID: 34324792
    [Abstract] [Full Text] [Related]

  • 7. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
    Honda K, Kadowaki S, Kato K, Hanai N, Hasegawa Y, Yatabe Y, Muro K.
    Invest New Drugs; 2019 Aug 16; 37(4):791-795. PubMed ID: 30790150
    [Abstract] [Full Text] [Related]

  • 8. Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.
    Reed DR, Hall RD, Gentzler RD, Volodin L, Douvas MG, Portell CA.
    Clin Lymphoma Myeloma Leuk; 2019 Jun 16; 19(6):e247-e250. PubMed ID: 30992232
    [No Abstract] [Full Text] [Related]

  • 9. Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
    Masuda N, Ohe Y, Gemma A, Kusumoto M, Yamada I, Ishii T, Yamamoto N.
    Cancer Sci; 2019 Apr 16; 110(4):1401-1407. PubMed ID: 30776174
    [Abstract] [Full Text] [Related]

  • 10. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
    Nagasaka M, Fisher A, Chowdhury T, Ge Y, Sukari A.
    Clin Lung Cancer; 2021 Jan 16; 22(1):e51-e53. PubMed ID: 32893122
    [No Abstract] [Full Text] [Related]

  • 11. A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib.
    Sakoda S, Tanaka K, Koga Y, Mikumo H, Tsuchiya-Kawano Y, Harada E, Tamiya S, Okamoto I.
    Thorac Cancer; 2024 Feb 16; 15(5):415-418. PubMed ID: 38213097
    [Abstract] [Full Text] [Related]

  • 12. Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion.
    Gaule M, Pesoni C, Quinzii A, Zecchetto C, Casalino S, Merz V, Contarelli S, Pietrobono S, Vissio E, Molinaro L, Manzin E, Volpatto R, Vellani G, Melisi D.
    JCO Precis Oncol; 2022 Jan 16; 6():e2100400. PubMed ID: 35005993
    [No Abstract] [Full Text] [Related]

  • 13. Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.
    Carneiro BA, Pamarthy S, Shah AN, Sagar V, Unno K, Han H, Yang XJ, Costa RB, Nagy RJ, Lanman RB, Kuzel TM, Ross JS, Gay L, Elvin JA, Ali SM, Cristofanilli M, Chae YK, Giles FJ, Abdulkadir SA.
    Clin Cancer Res; 2018 Jun 15; 24(12):2732-2739. PubMed ID: 29559559
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role and targeting of anaplastic lymphoma kinase in cancer.
    Della Corte CM, Viscardi G, Di Liello R, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F.
    Mol Cancer; 2018 Feb 19; 17(1):30. PubMed ID: 29455642
    [Abstract] [Full Text] [Related]

  • 16. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
    Song P, Zhang J, Shang C, Zhang L.
    Thorac Cancer; 2018 Oct 19; 9(10):1327-1332. PubMed ID: 30133144
    [Abstract] [Full Text] [Related]

  • 17. ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review.
    Kathuria-Prakash N, Lopez LP, Raman S, Ye H, Anaokar J, Sisk A, Pantuck AJ, Drakaki A.
    JCO Precis Oncol; 2024 Jun 19; 8():e2400154. PubMed ID: 38885453
    [Abstract] [Full Text] [Related]

  • 18. Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report.
    Sun K, Nie L, Nong L, Cheng Y.
    Thorac Cancer; 2021 Jun 19; 12(12):1927-1930. PubMed ID: 33960639
    [Abstract] [Full Text] [Related]

  • 19. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
    Hu J, Zhang B, Yao F, Fu Y, Chen D, Li D, Du N, Lizaso A, Song J, Zhang L, Li X.
    Ther Adv Respir Dis; 2020 Jun 19; 14():1753466620935770. PubMed ID: 32600123
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.